Benchmark analyst Robert Wasserman raised the firm’s price target on Halozyme (HALO) to $68 from $55 and keeps a Buy rating on the shares on growing earnings momentum as well as anticipation of pending U.S. approval of Argenx’s (ARGX) subcutaneous Vyvgart for generalized Myasthenia Gravis, or gMG.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HALO: